Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 15/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 15/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20418993 | 0.91 | TAS1R3 (0.42) | TAS1R3TAS1R1CNR2ASAH1HDAC7 | |
| SCHEMBL23872661 | 0.90 | ASAH1 (0.41) | TAS1R3TAS1R1CNR2ASAH1HDAC7 | |
| SCHEMBL12788565 | 0.81 | CA12 (0.46) | TAS1R3TAS1R1CNR2ASAH1CYP1A2 | |
| SCHEMBL27547888 | 0.80 | TAS1R3 (0.44) | TAS1R3TAS1R1 | |
| SCHEMBL23613007 | 0.80 | ALDH1A1 (0.43) | TAS1R3TAS1R1CNR2ASAH1HDAC7 | |
| SCHEMBL26412098 | 0.78 | CNR2 (0.37) | TAS1R3TAS1R1CNR2ASAH1HDAC7 | |
| SCHEMBL18880069 | 0.78 | GABRR1 (0.35) | CNR2CYP2C9CYP2C19 | |
| SCHEMBL8738364 | 0.77 | FPR2 (0.44) | ASAH1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL12965980 | 0.77 | CTSK (0.36) | TAS1R3TAS1R1CNR2ASAH1HDAC7 | |
| SCHEMBL10033051 | 0.76 | ASAH1 (0.39) | CNR2ASAH1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190209574-A1 | SUBSTITUTED 2, 3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | ARRIEN PHARMACEUTICALS LLC (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10682358-B2 | Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | RORA, RORB, RORC | TAS1R3 1117/4885TAS1R1 765/4885CNR2 314/4885 |
| US-20190209574-A1 | SUBSTITUTED 2, 3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS | RORA, RORB, RORC | TAS1R3 1117/4885TAS1R1 765/4885CNR2 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.